181 related articles for article (PubMed ID: 11245491)
1. Mechanism of functional inactivation of a Li-Fraumeni syndrome p53 that has a mutation outside of the DNA-binding domain.
Gu J; Kawai H; Wiederschain D; Yuan ZM
Cancer Res; 2001 Feb; 61(4):1741-6. PubMed ID: 11245491
[TBL] [Abstract][Full Text] [Related]
2. Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members.
Lomax ME; Barnes DM; Hupp TR; Picksley SM; Camplejohn RS
Oncogene; 1998 Aug; 17(5):643-9. PubMed ID: 9704930
[TBL] [Abstract][Full Text] [Related]
3. A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family.
Plummer SJ; Santibáñez-Koref M; Kurosaki T; Liao S; Noble B; Fain PR; Anton-Culver H; Casey G
Oncogene; 1994 Nov; 9(11):3273-80. PubMed ID: 7936651
[TBL] [Abstract][Full Text] [Related]
4. Linkage studies in a Li-Fraumeni family with increased expression of p53 protein but no germline mutation in p53.
Birch JM; Heighway J; Teare MD; Kelsey AM; Hartley AL; Tricker KJ; Crowther D; Lane DP; Santibáñez-Koref MF
Br J Cancer; 1994 Dec; 70(6):1176-81. PubMed ID: 7981072
[TBL] [Abstract][Full Text] [Related]
5. Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations.
Liu PK; Kraus E; Wu TA; Strong LC; Tainsky MA
Oncogene; 1996 Jun; 12(11):2267-78. PubMed ID: 8649766
[TBL] [Abstract][Full Text] [Related]
6. Leukemic and non-leukemic lymphocytes from patients with Li Fraumeni syndrome demonstrate loss of p53 function, Bcl-2 family dysregulation and intrinsic resistance to conventional chemotherapeutic drugs but not flavopiridol.
Pepper C; Thomas A; Hoy T; Tighe J; Culligan D; Fegan C; Bentley P
Cell Cycle; 2003; 2(1):53-8. PubMed ID: 12695689
[TBL] [Abstract][Full Text] [Related]
7. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
[TBL] [Abstract][Full Text] [Related]
8. Aberrant p21WAF1-dependent growth arrest as the possible mechanism of abnormal resistance to ultraviolet light cytotoxicity in Li-Fraumeni syndrome fibroblast strains heterozygous for TP53 mutations.
Barley RD; Enns L; Paterson MC; Mirzayans R
Oncogene; 1998 Aug; 17(5):533-43. PubMed ID: 9704919
[TBL] [Abstract][Full Text] [Related]
9. Functional studies of a novel germline p53 splicing mutation identified in a patient with Li-Fraumeni-like syndrome.
Piao J; Sakurai N; Iwamoto S; Nishioka J; Nakatani K; Komada Y; Mizutani S; Takagi M
Mol Carcinog; 2013 Oct; 52(10):770-6. PubMed ID: 22495821
[TBL] [Abstract][Full Text] [Related]
10. Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination.
Nakamura S; Roth JA; Mukhopadhyay T
Mol Cell Biol; 2000 Dec; 20(24):9391-8. PubMed ID: 11094089
[TBL] [Abstract][Full Text] [Related]
11. The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube.
Xian W; Miron A; Roh M; Semmel DR; Yassin Y; Garber J; Oliva E; Goodman A; Mehra K; Berkowitz RS; Crum CP; Quade BJ
J Pathol; 2010 Jan; 220(1):17-23. PubMed ID: 19834951
[TBL] [Abstract][Full Text] [Related]
12. Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family.
Lomax ME; Barnes DM; Gilchrist R; Picksley SM; Varley JM; Camplejohn RS
Oncogene; 1997 Apr; 14(15):1869-74. PubMed ID: 9150393
[TBL] [Abstract][Full Text] [Related]
13. RNA polymerase III transcription can be derepressed by oncogenes or mutations that compromise p53 function in tumours and Li-Fraumeni syndrome.
Stein T; Crighton D; Boyle JM; Varley JM; White RJ
Oncogene; 2002 May; 21(19):2961-70. PubMed ID: 12082526
[TBL] [Abstract][Full Text] [Related]
14. Genetic modeling of Li-Fraumeni syndrome in zebrafish.
Parant JM; George SA; Holden JA; Yost HJ
Dis Model Mech; 2010; 3(1-2):45-56. PubMed ID: 20075382
[TBL] [Abstract][Full Text] [Related]
15. DNA damage-associated dysregulation of the cell cycle and apoptosis control in cells with germ-line p53 mutation.
Goi K; Takagi M; Iwata S; Delia D; Asada M; Donghi R; Tsunematsu Y; Nakazawa S; Yamamoto H; Yokota J; Tamura K; Saeki Y; Utsunomiya J; Takahashi T; Ueda R; Ishioka C; Eguchi M; Kamata N; Mizutani S
Cancer Res; 1997 May; 57(10):1895-902. PubMed ID: 9157982
[TBL] [Abstract][Full Text] [Related]
16. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
[TBL] [Abstract][Full Text] [Related]
17. A functional variant in miR-605 modifies the age of onset in Li-Fraumeni syndrome.
Id Said B; Malkin D
Cancer Genet; 2015; 208(1-2):47-51. PubMed ID: 25683625
[TBL] [Abstract][Full Text] [Related]
18. Role of the ATPase domain of the Cockayne syndrome group B protein in UV induced apoptosis.
Balajee AS; Proietti De Santis L; Brosh RM; Selzer R; Bohr VA
Oncogene; 2000 Jan; 19(4):477-89. PubMed ID: 10698517
[TBL] [Abstract][Full Text] [Related]
19. Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein.
Liu WL; Midgley C; Stephen C; Saville M; Lane DP
J Mol Biol; 2001 Nov; 313(4):711-31. PubMed ID: 11697899
[TBL] [Abstract][Full Text] [Related]
20. p53+/mdm2- atypical lipomatous tumor/well-differentiated liposarcoma in young children: an early expression of Li-Fraumeni syndrome.
Debelenko LV; Perez-Atayde AR; Dubois SG; Grier HE; Pai SY; Shamberger RC; Kozakewich HP
Pediatr Dev Pathol; 2010; 13(3):218-24. PubMed ID: 20028212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
